EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET FORECAST 2022-2030

 

TABLE OF CONTENTS

 

1.     RESEARCH SCOPE & METHODOLOGY

1.1. STUDY OBJECTIVES

1.2. SCOPE OF STUDY

1.3. METHODOLOGY

1.4. ASSUMPTIONS & LIMITATIONS

2.     EXECUTIVE SUMMARY

2.1. MARKET SIZE & ESTIMATES

2.2. MARKET OVERVIEW

3.     MARKET DYNAMICS

3.1. PARENT MARKET ANALYSIS

3.2. KEY DRIVERS

3.2.1.   GROWING GERIATRIC POPULATION

3.2.2.   RISING PERVASIVENESS OF ALZHEIMER’S DISEASE

3.2.3.   EMERGING NOVEL DIAGNOSTIC TECHNOLOGIES

3.2.4.   INCREASING PIPELINE DRUGS

3.3. KEY RESTRAINTS

3.3.1.   FAILURE OF THE LATE-STAGE DRUGS

3.3.2.   STRINGENT GOVERNMENT REGULATIONS

3.3.3.   LACK OF THE AVAILABILITY OF SURROGATE MARKERS

4.     KEY ANALYTICS

4.1. TIMELINE OF ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET

4.2. PHASES AND STERNNESS OF ALZHEIMER’S DISEASE

4.3. IMPACT OF COVID-19 ON ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET

4.4. KEY MARKET TRENDS

4.5. PORTER’S FIVE FORCES ANALYSIS

4.5.1.   BUYERS POWER

4.5.2.   SUPPLIERS POWER

4.5.3.   SUBSTITUTION

4.5.4.   NEW ENTRANTS

4.5.5.   INDUSTRY RIVALRY

4.6. KEY BUYING CRITERIA

4.7. SUPPLY CHAIN ANALYSIS

4.8. OPPORTUNITY MATRIX

4.9. VENDOR LANDSCAPE

5.     MARKET BY THERAPEUTICS & DIAGNOSTICS

5.1. THERAPEUTICS

5.1.1.   DRUGS

5.1.1.1.        MARKETED DRUGS

5.1.1.2.        PIPELINE DRUGS

5.1.2.   DISEASE STAGE

5.1.2.1.        LATE-STAGE: SEVERE AD

5.1.2.2.        EARLY/MIDDLE STAGE: MILD TO MODERATE AD

5.1.2.3.        PRODROMAL STAGE

5.1.3.   GENERIC & BRANDED

5.1.3.1.        BRANDED

5.1.3.2.        GENERIC

5.2. DIAGNOSTICS

5.2.1.   LUMBAR PUNCTURE TEST

5.2.2.   POSITRON EMISSION TOMOGRAPHY

5.2.3.   ELECTROENCEPHALOGRAPHY

5.2.4.   MAGNETIC RESONANCE IMAGING

5.2.5.   COMPUTED TOMOGRAPHY

5.2.6.   BLOOD TEST

5.2.7.   OTHER DIAGNOSTICS

6.     GEOGRAPHICAL ANALYSIS

6.1. EUROPE

6.1.1.   MARKET SIZE & ESTIMATES

6.1.2.   KEY GROWTH ENABLERS

6.1.3.   KEY CHALLENGES

6.1.4.   KEY PLAYERS

6.1.5.   COUNTRY ANALYSIS

6.1.5.1.        UNITED KINGDOM

6.1.5.2.        GERMANY

6.1.5.3.        FRANCE

6.1.5.4.        ITALY

6.1.5.5.        BELGIUM

6.1.5.6.        POLAND

6.1.5.7.        REST OF EUROPE

7.     COMPETITIVE LANDSCAPE

7.1. KEY STRATEGIC DEVELOPMENTS

7.1.1.   MERGERS & ACQUISITIONS

7.1.2.   PRODUCT LAUNCHES & DEVELOPMENTS

7.1.3.   PARTNERSHIPS & AGREEMENTS

7.1.4.   BUSINESS EXPANSIONS, ANNOUNCEMENTS, & DIVESTITURES

7.2. COMPANY PROFILES

7.2.1.   ALLERGAN PLC (ACQUIRED BY ABBVIE)

7.2.2.   AMARANTUS BIOSCIENCE HOLDINGS INC

7.2.3.   BAXTER INTERNATIONAL INC

7.2.4.   BIOGEN INC

7.2.5.   COGNOPTIX INC

7.2.6.   EISAI CO LTD

7.2.7.   ELI LILLY & COMPANY

7.2.8.   F HOFFMANN-LA ROCHE

7.2.9.   GE HEALTHCARE

7.2.10.                    JOHNSON & JOHNSON

7.2.11.                    LUPIN LIMITED

7.2.12.                    MERCK & CO INC

7.2.13.                    NOVARTIS AG

7.2.14.                    PFIZER INC

7.2.15.                    SIEMENS HEALTHINEERS AG

7.2.16.                    SUN PHARMACEUTICALS INDUSTRIES LTD

7.2.17.                    TEVA PHARMACEUTICAL INDUSTRIES LIMITED

7.2.18.                    ZYDUS CADILA

 

LIST OF TABLES

 

TABLE 1: MARKET SNAPSHOT - ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS

TABLE 2: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY THERAPEUTICS & DIAGNOSTICS, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 3: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY THERAPEUTICS & DIAGNOSTICS, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 4: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUGS, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 5: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUGS, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 6: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 7: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 8: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 9: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 10: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY DIAGNOSTICS, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 11: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY DIAGNOSTICS, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 12: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 13: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 14: LEADING PLAYERS OPERATING IN EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET

TABLE 15: LIST OF MERGERS & ACQUISITIONS

TABLE 16: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS

TABLE 17: LIST OF PARTNERSHIPS & AGREEMENTS

TABLE 18: LIST OF BUSINESS EXPANSIONS, ANNOUNCEMENTS, & DIVESTITURES

 

LIST OF FIGURES

 

FIGURE 1: PIPELINE DRUGS RELATED TO ALZHEIMER’S DISEASE

FIGURE 2: KEY MARKET TRENDS

FIGURE 3: PORTER’S FIVE FORCES ANALYSIS

FIGURE 4: KEY BUYING CRITERIA

FIGURE 5: SUPPLY CHAIN ANALYSIS

FIGURE 6: OPPORTUNITY MATRIX

FIGURE 7: VENDOR LANDSCAPE

FIGURE 8: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY THERAPEUTICS & DIAGNOSTICS, IN 2021

FIGURE 9: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY THERAPEUTICS, 2022-2030 (IN $ MILLION)

FIGURE 10: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET, GROWTH POTENTIAL, BY DRUGS, IN 2021

FIGURE 11: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY MARKETED DRUGS, 2022-2030 (IN $ MILLION)

FIGURE 12: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY PIPELINE DRUGS, 2022-2030 (IN $ MILLION)

FIGURE 13: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET, GROWTH POTENTIAL, BY DISEASE STAGE, IN 2021

FIGURE 14: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY LATE-STAGE: SEVERE AD, 2022-2030 (IN $ MILLION)

FIGURE 15: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY EARLY/MIDDLE STAGE: MILD TO MODERATE AD, 2022-2030 (IN $ MILLION)

FIGURE 16: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY PRODROMAL STAGE, 2022-2030 (IN $ MILLION)

FIGURE 17: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET, GROWTH POTENTIAL, BY GENERIC & BRANDED, IN 2021

FIGURE 18: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY BRANDED, 2022-2030 (IN $ MILLION)

FIGURE 19: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC, 2022-2030 (IN $ MILLION)

FIGURE 20: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2022-2030 (IN $ MILLION)

FIGURE 21: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY DIAGNOSTICS, IN 2021

FIGURE 22: EUROPE ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY LUMBAR PUNCTURE TEST, 2022-2030 (IN $ MILLION)

FIGURE 23: EUROPE ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY POSITRON EMISSION TOMOGRAPHY, 2022-2030 (IN $ MILLION)

FIGURE 24: EUROPE ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY ELECTROENCEPHALOGRAPHY, 2022-2030 (IN $ MILLION)

FIGURE 25: EUROPE ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY MAGNETIC RESONANCE IMAGING, 2022-2030 (IN $ MILLION)

FIGURE 26: EUROPE ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY COMPUTED TOMOGRAPHY, 2022-2030 (IN $ MILLION)

FIGURE 27: EUROPE ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY BLOOD TEST, 2022-2030 (IN $ MILLION)

FIGURE 28: EUROPE ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY OTHER DIAGNOSTICS, 2022-2030 (IN $ MILLION)

FIGURE 29: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)

FIGURE 30: UNITED KINGDOM ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 31: GERMANY ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 32: FRANCE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 33: ITALY ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 34: BELGIUM ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 35: POLAND ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 36: REST OF EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

 

KEY FINDINGS

 

The Europe Alzheimer’s disease therapeutics & diagnostics market is set to grow with a 6.80% CAGR between the estimated period 2022 and 2030. The rising mortality rate in the region and government efforts to promote awareness about the disease are propelling the market surge.

 

Get more Insights into the Europe Alzheimer’s Disease Therapeutics & Diagnostics Market:

https://inkwoodresearch.com/reports/europe-alzheimers-therapeutics-and-diagnostics-market/

 

MARKET INSIGHTS

The Europe Alzheimer’s disease therapeutics & diagnostics market growth assessment entails the evaluation of France, Germany, Italy, Poland, Belgium, United Kingdom, and Rest of Europe. France created a network of ‘memory centers,’ highly specialized in diagnosing neurodegenerative disorders. Also, the government launched the French National Plan for neurodegenerative diseases for 2014-2019. The plan included three main priorities for improving the diagnosis and treatment of patients, ensuring patients’ quality of life, while developing and coordinating research.

In addition, the high geriatric population prompted the Italian government to lead the preparation of effective drugs for Alzheimer’s disease (AD) as soon as possible. Moreover, due to the COVID-19 outbreak, the country’s clinical trials are expected to increase slowly. According to the Alzheimer Europe 2019 report, the number of people suffering from dementia in Italy is projected to double by 2050. As the number of people suffering from dementia is expected to double in the next few years, the market is expected to witness growth in the country over the forecast period.

Furthermore, Alzheimer’s Europe estimated the number of people with dementia in Belgium in 2012 as being 1,91,281, which is likely to increase over the decade. In 2016, health spending accounted for 10% of Belgian Gross Domestic and was likely to increase over the coming years, driving the market growth.

COMPETITIVE INSIGHTS

Some of the key players in the market include GE Healthcare, Novartis AG, Pfizer Inc, etc.

Our report offerings include:

·       Explore key findings of the overall market

·       Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)

·       Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions

·       Market Segmentation caters to a thorough assessment of key segments with their market estimations

·       Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share

·       Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.

·       Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.

·       Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

 

SEGMENTATION

1.    ALLERGAN PLC (ACQUIRED BY ABBVIE)

2.    AMARANTUS BIOSCIENCE HOLDINGS INC

3.    BAXTER INTERNATIONAL INC

4.    BIOGEN INC

5.    COGNOPTIX INC

6.    EISAI CO LTD

7.    ELI LILLY & COMPANY

8.    F HOFFMANN-LA ROCHE

9.    GE HEALTHCARE

10.          JOHNSON & JOHNSON

11.          LUPIN LIMITED

12.          MERCK & CO INC

13.          NOVARTIS AG

14.          PFIZER INC

15.          SIEMENS HEALTHINEERS AG

16.          SUN PHARMACEUTICALS INDUSTRIES LTD

17.          TEVA PHARMACEUTICAL INDUSTRIES LIMITED

18.          ZYDUS CADILA